Show simple item record

dc.contributor.authorDilege, Sukru
dc.contributor.authorEralp, Yeşim
dc.contributor.authorToker, Alper
dc.contributor.authorOral, Ethem Nezih
dc.contributor.authorTas, Faruk
dc.contributor.authorSen, Fatma
dc.contributor.authorSAGLAM, Esra Kaytan
dc.contributor.authorAydiner, Adnan
dc.date.accessioned2021-03-03T16:48:56Z
dc.date.available2021-03-03T16:48:56Z
dc.date.issued2011
dc.identifier.citationAydiner A., Sen F., SAGLAM E. K. , Oral E. N. , Eralp Y., Tas F., Toker A., Dilege S., "Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study", CLINICAL LUNG CANCER, cilt.12, sa.5, ss.286-292, 2011
dc.identifier.issn1525-7304
dc.identifier.othervv_1032021
dc.identifier.otherav_465c714f-2f4b-4096-9e15-9b5aad36cfd9
dc.identifier.urihttp://hdl.handle.net/20.500.12627/50901
dc.identifier.urihttps://doi.org/10.1016/j.cllc.2011.03.030
dc.description.abstractBackground: The main goal of this study was to evaluate the feasibility and effectivity of triweekly docetaxel/cisplatin followed by weekly docetaxel/cisplatin concomitantly with radiotherapy with or without surgery in locally advanced non-small-cell lung cancer (NSCLC) patients. Materials and Methods: Thirty five patients with locally advanced NSCLC were enrolled. Combination chemotherapy with triweekly docetaxel/cisplatin (75 mg/m(2)) was administered as induction regimen. After induction chemotherapy, patients were evaluated for surgery if their disease subsequently downstaged. Six cycles of weekly docetaxel/cisplatin (20 mg/m(2)) concurrently with radiotherapy up to a 60 Gy were administered after induction chemotherapy with or without surgery. Response, toxicity, time-to-progression and overall survival were evaluated. Results: Twelve patients with stage IIIA-N2 and 23 patients with stage IIIB-T4N0-2 were evaluated (median age, 54 years). After 94 cycles of induction chemotherapy, partial response was achieved in 20 patients, 9 patients had stable disease and six had progressive disease. After overall treatment, 6 patients achieved complete response, 19 patients had partial response, 8 patients had progressive disease, and 2 patients had stable disease. Two patients experienced grade 3-4 pulmonary toxicity and 1 patient experienced grade 3 esophageal toxicity. Six patients underwent surgery. Median overall survival for all patients was 15 months and time-to-progression was 13 months with a median follow-up of 22 months. Conclusion: Triweekly docetaxel plus cisplatin followed by weekly docetaxel plus cisplatin concomitantly with radiotherapy is effective and feasible and seems to be an alternative option for patients who have locally advanced NSCLC. Surgery may provide additional benefit for patients whose disease adequately downstaged after induction chemotherapy.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleInduction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study
dc.typeMakale
dc.relation.journalCLINICAL LUNG CANCER
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume12
dc.identifier.issue5
dc.identifier.startpage286
dc.identifier.endpage292
dc.contributor.firstauthorID21234


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record